Mass Balance Study of the Engineered Cationic Antimicrobial Peptide, WLBU2, Following a Single Intravenous Dose of 14C-WLBU2 in Mice

BACKGROUND: To address multidrug resistance, we developed engineered cationic antimicrobial peptides (eCAPs). Lead eCAP WLBU2 displays potent activity against drug-resistant bacteria and effectively treats lethal bacterial infections in mice, reducing bacterial loads to undetectable levels in divers...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Curr Rev Clin Exp Pharmacol
Päätekijät: Beumer, Jan H., Guo, Jianxia, Ray, Evan C., Scemama, Jonas, Parise, Robert A., Deslouches, Berthony, Steckbeck, Jonathan D., Montelaro, Ronald C., Eiseman, Julie L.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2021
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8083974/
https://ncbi.nlm.nih.gov/pubmed/32778037
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2174/1574884715666200810094201
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia